My watch list
my.bionity.com  
Login  

GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases

13-Nov-2014

GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases.

Liver disease has almost no visible symptoms, and its progress is characterized by a hardening of the tissues due to fibrosis accompanying the inflammation of the liver and a worsening of symptoms due to cirrhosis. Amid such worldwide trends of recent years as the aging population and less healthy lifestyle habits, non-alcoholic fatty liver disease (NAFLD) has emerged as a type of metabolic syndrome.

Over the past couple of decades, NAFLD and non-alcoholic steatohepatitis (NASH) have become the number one cause of liver disease in developed countries. The prevalence of NAFLD has doubled during the last 20 years, whereas the prevalence of other chronic liver diseases has remained stable or even decreased. More recent data confirm that NAFLD and NASH play an equally important role in developing regions like the Middle East, Far East, Africa, the Caribbean, and Latin America. 2 Early diagnosis of hepatic fibrosis as well as the development of drugs to control the progression of liver disease has become important issues.

According to the alliance agreement, GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the research and development work Takeda is conducting on liver diseases. By optimizing the strengths of both companies in the alliance, the collaborative effort aims to help develop therapeutic drugs as well as new diagnostic technologies for liver diseases.

Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy, in which a needle is inserted through the skin into the liver, a sample of which is then removed for measurement. With MR elastography commercialized by GE Healthcare, in use in the United States since 2009 and in Japan since 2012, it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner. It is expected that this kind of GE Healthcare diagnostic technology will contribute to Takeda's efforts to develop innovative medicines.

Facts, background information, dossiers
  • GE Healthcare
  • hepatic fibrosis
  • Takeda Pharmaceuticals
  • non-alcoholic steat…
More about GE Healthcare
More about Takeda Pharma
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE